dr. west on fda approval of afatinib in nsclc with rare egfr mutations
Published 6 years ago • 397 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
4:06
afatinib in patients with uncommon egfr mutations
-
0:51
dr. west discusses afatinib and cetuximab combination in nsclc
-
2:03
dr. west on considering factors for egfr tkis in nsclc
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
0:58
the activity of afatinib in lung cancer
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
4:09
frontline afatinib in egfr-mutant nsclc
-
6:36
a new treatment option for uncommon egfr mutations (bmic-023)
-
1:16
dr. scagliotti on treating egfr-mutated tumors with afatinib
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc